Literature DB >> 15234033

The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma.

Min Yao1, Michael M Graham, Henry T Hoffman, Russell B Smith, Gerry F Funk, Scott M Graham, Kenneth J Dornfeld, Mark Skwarchuk, Yusuf Menda, John M Buatti.   

Abstract

PURPOSE: The role of neck dissection after radiation therapy ([RT] with or without chemotherapy) for regionally advanced head and neck cancer is controversial. As much as 50% of residual lymphadenopathy after radiation has no viable tumor cells present on histopathologic analysis. [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) imaging can detect metabolically active cancer. This study examines the ability of post-RT FDG PET imaging to predict the tumor status of residual lymphadenopathy after nonsurgical management of regionally advanced neck disease. METHODS AND MATERIAL: From February 2000 to October 2002, 41 patients were treated definitively by radiation (with or without chemotherapy) and underwent FDG PET and computed tomography (CT) imaging after treatment to assess response. Patients with negative CT and FDG PET scans were observed and did not undergo neck dissection. Patients with radiographically persistent lymphadenopathy underwent either neck dissection or fine-needle aspiration of the lymph nodes using ultrasound guidance. The results of the FDG PET scans were correlated with the pathologic findings.
RESULTS: Twelve patients with persistent lymphadenopathy underwent either neck dissection or fine-needle aspiration. Four of the 12 were found to have viable residual tumor in the cervical lymph nodes. The pathology did not correlate with the size of the lymph nodes in the pre-RT or post-RT CT studies. However, the pathology correlated strongly with the post-RT FDG PET studies. All patients with a negative post-RT FDG PET or those with a maximum standardized uptake value (SUV(max)) of less than 3.0 in the post-RT FDG PET were found to be free of residual viable tumor. Using an SUV(max) of less than 3.0 as the criterion for a negative FDG PET study, the negative predictive value was 100% and the positive predictive value was 80%.
CONCLUSIONS: A negative post-RT FDG PET scan is very predictive of negative pathology in neck dissection or fine-needle aspiration even with large residual lymphadenopathy. Therefore, if the post-RT FDG PET scan is negative, neck dissection might not be required for regional control. A prospective study with longer follow-up and greater patient numbers is needed to determine whether a policy of deferring neck dissection based on a negative FDG PET is supported.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234033     DOI: 10.1016/j.ijrobp.2004.01.040

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

Review 1.  The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients.

Authors:  Joji Kawabe; Shigeaki Higashiyama; Atsushi Yoshida; Kohei Kotani; Susumu Shiomi
Journal:  Jpn J Radiol       Date:  2012-04-05       Impact factor: 2.374

2.  Evaluation of neck node response after radiotherapy: minimizing equivocal results.

Authors:  Remco de Bree; Otto S Hoekstra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04       Impact factor: 9.236

3.  Head and neck cancer: how imaging predicts treatment outcome.

Authors:  Robert Hermans
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

4.  Tumour volumes: Predictors of early treatment response in locally advanced head and neck cancers treated with definitive chemoradiation.

Authors:  Parveen Ahlawat; Sheh Rawat; Anjali Kakria; Manoj Pal; Deepika Chauhan; Sarthak Tandon; Shraddha Jain
Journal:  Rep Pract Oncol Radiother       Date:  2016-05-05

5.  Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522.

Authors:  David L Schwartz; Jonathan Harris; Min Yao; David I Rosenthal; Adam Opanowski; Anthony Levering; K Kian Ang; Andy M Trotti; Adam S Garden; Christopher U Jones; Paul Harari; Robert Foote; John Holland; Qiang Zhang; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-15       Impact factor: 7.038

6.  Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.

Authors:  Carryn M Anderson; Tangel Chang; Michael M Graham; Michael D Marquardt; Anna Button; Brian J Smith; Yusuf Menda; Wenqing Sun; Nitin A Pagedar; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-30       Impact factor: 7.038

Review 7.  Positron emission tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma.

Authors:  Voichita Bar-Ad; Mark Mishra; Nitin Ohri; Charles Intenzo
Journal:  Rev Recent Clin Trials       Date:  2012-02

8.  Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length?

Authors:  Reubendra Jeganathan; James McGuigan; Frederick Campbell; Thomas Lynch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-16       Impact factor: 9.236

Review 9.  Contribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment.

Authors:  Carlos Ferrer Albiach; Antonio Conde Moreno; Marta Rodríguez Cordón; Virginia Morillo Macías; Ana Bouché Babiloni; Inmaculada Beato Tortajada; Angel Sánchez Iglesias; Alicia Francés Muñoz
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

10.  Preoperative [18F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse.

Authors:  Chun-Ta Liao; Joseph Tung-Chieh Chang; Hung-Ming Wang; Shu-Hang Ng; Shiang-Fu Huang; I-How Chen; Chuen Hsueh; Li-Yu Lee; Chih-Hung Lin; Ann-Joy Cheng; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.